LECIP-ARCONTIA
9.12.2020 10:02:07 CET | Business Wire | Press release
A modern standard device for e-ticketing – the EMV Level 2 Certified LECIP Validator “LV-700” provides public transport authorities with great access to contactless ticketing. The state-of-the-art validator is compliant with VDV-KA and a great enhancement to the end-to-end ticketing solutions from the IVU.suite. LECIP Arcontia AB has agreed to supply IVU Traffic Technologies AG with the LV-700 validator as an integrated part of their IVU.suite product line-up.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005021/en/
LECIP ARCONTIA AB and IVU Traffic Technologies AG have concluded a non-exclusive partnership on the distribution of LECIP’s on-board validator “LV-700” which IVU will offer as part of their integrated, one-stop solution IVU.suite. Being EMV L1/L2 compliant, LV-700 will provide a wide variety of payment solutions as an important device of contactless ticketing solutions.
The LV-700 series is designed for fast and smooth cashless and contactless payment with a high-speed processor and large capacity memory for demanding ticket data processing. Contactless payment by using credit cards has become very popular around the globe, preventing crimes such as skimming, and making payment more convenient and secure.
Within the IVU.suite, the IVU.validator-branded LV-700 will play an important role supporting the end-to-end ticketing solutions IVU.fare and IVU.ticket as well as the driver operated on-board computer IVU.ticket.box. By enabling the customers to make quick and uncomplicated cashless payments, the IVU.validator takes some of the pressure from the driver and makes boarding faster.
“As we are migrating our platform to Linux we are excited to be partnering with LECIP Arcontia and start implementing their LV-700 in our upcoming projects,” says Henrik Benner, Head of Equipment Development at IVU Traffic Technologies AG. “Thanks to its VDV-KA compliance and its future proof technology, the validator is a great tool for a more contactless future, and we are looking forward to introducing it to our customers.”
LECIP ARCONTIA AB, a subsidiary of LECIP HOLDINGS CORPORATION (TOKYO: 7213) of Gifu, Japan, operates globally to deliver contactless smart card products and solutions for Automated Fare Collection System (AFC). We develop and distribute smart card readers and terminals used in over 40 countries. Our focus is to deliver reliable, high quality contactless smart card products, and implement software services featuring the latest technology and market requirements in e-ticketing and payment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom